Chronic Oral Graft-versus-host Disease: Clinical Risk Factors, Biochemical Markers Of Disease Activity And Novel Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$134,184.00
Summary
Chronic graft-versus-host disease (GVHD) is a serious complication of bone marrow transplantation. The oral cavity is often affected. Aims: 1.Identify and validate risk factors for oral GVHD 2.Assess if specific salivary components reflect disease activity 3.Trial novel therapeutic for GVHD-associated dry mouth Saliva testing may offer a non-invasive method to monitor oral GVHD. Also, new and effective topical agents are greatly needed and will improve therapeutic options in oral GVHD
Targeting Transcriptional Addiction For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
.Tumours driven by the oncogene “Myc” are difficult to treat and an effective means to directly target Myc using small molecules has proven elusive. We have discovered that Myc-dependent tumours are dependent on their ability to globally amplify gene expression through a mechanism that involves the CDK9 enzyme and possibly other related enzymes. I will test the effectiveness of targeting CDK9 in a range of tumours with a Myc dependency, both alone and in combination with other small molecules.
Improving The Long-term Outcomes Of The Australian And New Zealand Fontan Population
Funder
National Health and Medical Research Council
Funding Amount
$89,836.00
Summary
The Fontan procedure is the last of a series of operations offered to children born with hearts with a single pumping chamber. Without this procedure these children would die, however, with this procedure their long-term expectations are still uncertain. This study will investigate the long-term outcomes of the Australian and New Zealand Fontan population and how these outcomes can be improved.
Tissue factor is a central and major player in the clotting process. It exists in both active and inactive forms. The active form initiates clot formation. How it gets activated is one of the most important unanswered questions in this area of research. Our aim is to discover tissue factorÍs mechanism of activation. The outcome will provide more specific targets for therapeutic drug development for cardiovascular disease, strokes and deep venous thrombosis.